Canada Pension Plan Investment Board Trims Stake in Astera Labs, Inc. $ALAB

Canada Pension Plan Investment Board reduced its position in shares of Astera Labs, Inc. (NASDAQ:ALAB - Free Report) by 77.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,200 shares of the company's stock after selling 155,600 shares during the period. Canada Pension Plan Investment Board's holdings in Astera Labs were worth $2,697,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Astera Labs by 2,824.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 154,524 shares of the company's stock valued at $20,467,000 after buying an additional 149,240 shares during the period. Aigen Investment Management LP grew its holdings in Astera Labs by 50.9% in the first quarter. Aigen Investment Management LP now owns 17,920 shares of the company's stock worth $1,069,000 after purchasing an additional 6,045 shares during the period. Pacific Point Advisors LLC grew its holdings in Astera Labs by 75.0% in the first quarter. Pacific Point Advisors LLC now owns 7,000 shares of the company's stock worth $418,000 after purchasing an additional 3,000 shares during the period. Oppenheimer Asset Management Inc. grew its holdings in shares of Astera Labs by 73.6% during the first quarter. Oppenheimer Asset Management Inc. now owns 15,995 shares of the company's stock valued at $954,000 after buying an additional 6,783 shares during the last quarter. Finally, Taylor Frigon Capital Management LLC purchased a new stake in shares of Astera Labs during the first quarter valued at approximately $1,887,000. 60.47% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ALAB. Northland Capmk cut shares of Astera Labs from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 22nd. Zacks Research upgraded shares of Astera Labs to a "strong-buy" rating in a report on Tuesday, August 12th. Stifel Nicolaus set a $145.00 target price on shares of Astera Labs and gave the stock a "buy" rating in a report on Monday, August 4th. Northland Securities downgraded shares of Astera Labs from an "outperform" rating to a "market perform" rating and set a $120.00 target price on the stock. in a report on Tuesday, July 22nd. Finally, Wall Street Zen upgraded shares of Astera Labs from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $142.00.

Astera Labs Trading Up 1.4%

ALAB stock opened at $176.61 on Thursday. Astera Labs, Inc. has a 12 month low of $36.85 and a 12 month high of $199.47. The company has a 50-day moving average price of $137.83 and a 200 day moving average price of $97.51. The stock has a market cap of $29.36 billion, a PE ratio of 315.38, a P/E/G ratio of 4.62 and a beta of 1.48.

Astera Labs (NASDAQ:ALAB - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.11. The company had revenue of $191.93 million during the quarter, compared to analysts' expectations of $172.46 million. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. The firm's quarterly revenue was up 149.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.13 EPS. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. Sell-side analysts forecast that Astera Labs, Inc. will post 0.34 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Jitendra Mohan sold 91,441 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $183.51, for a total value of $16,780,337.91. Following the completion of the sale, the chief executive officer owned 2,170,877 shares in the company, valued at approximately $398,377,638.27. The trade was a 4.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Philip Mazzara sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $188.70, for a total transaction of $1,887,000.00. Following the transaction, the general counsel owned 161,573 shares of the company's stock, valued at approximately $30,488,825.10. This trade represents a 5.83% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,649,489 shares of company stock worth $232,463,986. 12.50% of the stock is owned by corporate insiders.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.